Italia markets close in 6 hours 36 minutes

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,4700-0,0200 (-1,34%)
Alla chiusura: 04:00PM EDT
1,5087 +0,04 (+2,63%)
Dopo ore: 07:17PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,4900
Aperto1,5000
Denaro1,4300 x 100
Lettera1,5200 x 100
Min-Max giorno1,4600 - 1,5000
Intervallo di 52 settimane1,4600 - 3,8200
Volume81.623
Media Volume91.048
Capitalizzazione24,676M
Beta (5 anni mensile)0,87
Rapporto PE (ttm)N/D
EPS (ttm)-2,7000
Prossima data utili07 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A6,00
  • GlobeNewswire

    UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

    Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF treatment and switched to UBX1325 monotherapy at study start maintained visual acuity through 24 weeks and had only a 1.5 letter decrease from baseline at week 48 40% of UBX1325-treated patients did not require anti-VEGF treatment through 48 weeks and 64%

  • GlobeNewswire

    UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. “We are focused on rapidly advancing UBX1325 (foselutoclax) into the next clinical study to help patients suffering from diabetic macular edema who receive suboptimal benefit from the current anti-VEGF standard of care,

  • GlobeNewswire

    UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)

    Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel senolytic therapeutic candidate to be evaluated head-to-head against standard of care anti-VEGF in DME SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging